BIO-Europe Spring® 2014: Go big or go home: When to go against the trends in R&D and dealmaking

March 27, 2014
Every pharma company boasts about being innovation-driven, yet most of their R&D targets and approaches are the same. Is there an R&D "fashion victim syndrome" that makes everyone invest in the same spaces? Who is preventing true innovation? Company boards? The regulators? Ourselves? Executives from pharma discuss why going into unpopular areas alone can actually be wildly successful. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/479
Previous Video
BIO-Europe Spring® 2014: Dealmaking strategies around orphan diseases
BIO-Europe Spring® 2014: Dealmaking strategies around orphan diseases

In recent years, orphan diseases have turned from ""do not touch"" to everyone's darling. With vast unmet m...

Next Video
BIO-Europe Spring® 2014: Pharma steps up early on relevance data
BIO-Europe Spring® 2014: Pharma steps up early on relevance data

For valuations on biotech/pharma deals, one principle has been inviolate: later stage programs, especially ...